A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
NCT ID: NCT04214288
Last Updated: 2025-11-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
240 participants
INTERVENTIONAL
2020-04-22
2026-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
NCT01597388
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
NCT02216786
AKT Inhibitor in Oestrogen Positive Breast Cancer
NCT02077569
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
NCT00679783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After the screening visit and confirmation of eligibility, patients will be randomly assigned in a 1:1:1:1 ratio to receive 1 of the following 4 treatments, consisting of 4-week treatment cycles until disease progression (assessed by the Investigator as defined by Response Evaluation Criteria in Solid Tumours \[RECIST\] version 1.1):
* AZD9833 (Dose A)
* AZD9833 (Dose B)
* AZD9833 (Dose C)
* Fulvestrant (500 mg) During the treatment period, patients will have scheduled visits until treatment discontinuation. After the end of treatment, patients will attend 2 safety follow-up visits (at the time of treatment discontinuation and 28 days later) and will continue to be followed for survival.
As of December 2020, the Sponsor stopped enrolment to Dose C.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD9833 Dose A
The patients will receive AZD9833 (Dose A).
AZD9833
Dosage formulation: AZD9833 tablets will be administered orally.
AZD9833 Dose B
The patients will receive AZD9833 (Dose B).
AZD9833
Dosage formulation: AZD9833 tablets will be administered orally.
AZD9833 Dose C
The patients will receive AZD9833 (Dose C).
AZD9833
Dosage formulation: AZD9833 tablets will be administered orally.
Fulvestrant 500 mg
The patients will receive Fulvestrant (500 mg).
Fulvestrant
Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD9833
Dosage formulation: AZD9833 tablets will be administered orally.
Fulvestrant
Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic or loco-regionally recurrent ER-positive HER2-negative adenocarcinoma of the breast.
* Radiological or other objective evidence of progression on or after the last systemic therapy prior to starting study treatment.
* Patients must have at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter or in absence of measurable disease as defined above, at least 1 lytic or mixed (lytic+sclerotic) bone lesion.
* Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1.
* Prior endocrine therapy as follows:
1. Recurrence or progression on at least one line of endocrine therapy
2. No more than 1 line of endocrine therapy for advanced disease
3. No more than 1 line of chemotherapy for advanced disease
4. Prior treatment with CDK4/6 inhibitors is permitted
5. No prior treatment with fulvestrant, oral selective oestrogen receptor degrader (SERD), or related therapies
* Inclusion criterion for the paired tumour biopsy research subgroup:
Washout from prior tamoxifen: 4 months to elapse from last tamoxifen dose to pre-dose on-study biopsy.
Exclusion Criteria
* Any cytotoxic chemotherapy, investigational agents or other anti-cancer drugs for the treatment of breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
* Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior to the first dose of study treatment.
* Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 3A4/5 and sensitive CYP2B6 substrates, and drugs which are substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index or inability to stop use within the washout period prior to receiving the first dose of study treatment.
* Drugs that are known to prolong QT and have a known risk of torsades de pointes.
* The following cardiovascular criteria: QTcF \>470 ms, resting heart rate \<45 bpm, clinically significant abnormalities of resting electrocardiogram, uncontrolled hypertension, symptomatic hypotension, factors that increase the risk for QTc prolongation, left ventricular ejection fraction \<50%.
* Radiotherapy with a limited field of radiation for palliation within 1 week of dosing, or to \> 30% of bone marrow or a wide field within 4 weeks of dosing.
* Major surgical procedure or significant traumatic injury.
* Presence of life-threatening metastatic visceral disease or uncontrolled central nervous system metastatic disease.
* Inadequate bone marrow reserve or organ function.
* Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833.
* History of hypersensitivity to active or inactive excipients of AZD9833 or fulvestrant.
* Previous randomisation in the present study.
* Women of childbearing potential.
18 Years
130 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Long Beach, California, United States
Research Site
Fort Myers, Florida, United States
Research Site
St. Petersburg, Florida, United States
Research Site
Lincoln, Nebraska, United States
Research Site
Canton, Ohio, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Eagle River, Wisconsin, United States
Research Site
Brasschaat, , Belgium
Research Site
Charleroi, , Belgium
Research Site
Ghent, , Belgium
Research Site
Haine-Saint-Paul, , Belgium
Research Site
Leuven, , Belgium
Research Site
Libramont-Chevigny, , Belgium
Research Site
Namur, , Belgium
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Paris, , France
Research Site
Vandœuvre-lès-Nancy, , France
Research Site
Batumi, , Georgia
Research Site
Tbilisi, , Georgia
Research Site
Tbilisi, , Georgia
Research Site
Tbilisi, , Georgia
Research Site
Tbilisi, , Georgia
Research Site
Tbilisi, , Georgia
Research Site
Berlin, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Essen, , Germany
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Kaposvár, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Pécs, , Hungary
Research Site
Szeged, , Hungary
Research Site
Jerusalem, , Israel
Research Site
Jerusalem, , Israel
Research Site
Nahariya, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Bologna, , Italy
Research Site
Catanzaro, , Italy
Research Site
Meldola, , Italy
Research Site
Messina, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Monza, , Italy
Research Site
Napoli, , Italy
Research Site
Roma, , Italy
Research Site
Umbria, , Italy
Research Site
Bydgoszcz, , Poland
Research Site
Lodz, , Poland
Research Site
Piła, , Poland
Research Site
Rzeszów, , Poland
Research Site
Skorzewo, , Poland
Research Site
Warsaw, , Poland
Research Site
Almada, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Kazan', , Russia
Research Site
Krasnodar, , Russia
Research Site
Kursk, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Pyatigorsk, , Russia
Research Site
Ryazan, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Volgograd, , Russia
Research Site
Goyang-si, , South Korea
Research Site
Incheon, , South Korea
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Seville, , Spain
Research Site
Zaragoza, , Spain
Research Site
Cherkasy, , Ukraine
Research Site
Chernivtsі, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
M. Kyiv, , Ukraine
Research Site
S. Khodosivka, , Ukraine
Research Site
Uzhhorod, , Ukraine
Research Site
Derby, , United Kingdom
Research Site
Leicester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Ajimi M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, van Zyl R, Arkania E. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024 Nov;25(11):1424-1439. doi: 10.1016/S1470-2045(24)00387-5.
Hamilton E, Oliveira M, Turner N, Garcia-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504974-40-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2019-003706-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D8530C00002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.